SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Baumann P, Hiemke C, Ulrich S et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004; 37: 243265.
  • 2
    Task Force on the Use of Laboratory Tests in Psychiatry. Tricyclic antidepressants: Blood level measurements and clinical outcome: An APA Task Force report. Am. J. Psychiatry 1985; 142: 155162.
  • 3
    Orsulak PJ. Therapeutic monitoring of antidepressant drugs: Guidelines updated. Ther. Drug Monit. 1989; 11: 497507.
  • 4
    Preskorn SH, Fast GA. Therapeutic drug monitoring for antidepressants: Efficacy, safety, and cost effectiveness. J. Clin. Psychiatry 1991; 52 (Suppl.): 2333.
  • 5
    Perry PJ, Zeilmann C, Arndt S. Tricyclic antidepressant concentrations in plasma: An estimate of their sensitivity and specificity as a predictor of response. J. Clin. Psychopharmacol. 1994; 14: 230240.
  • 6
    Rodriguez de la Torre B, Dreher J, Malevany I et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther. Drug Monit. 2001; 23: 435440.
  • 7
    Ulrich S, Lauter J. Comprehensive survey of the relationship between serum concentration and therapeutic effect of amitriptyline in depression. Clin. Pharmacokinet. 2002; 41: 853876.
  • 8
    Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am. J. Epidemiol. 1992; 136: 873883.
  • 9
    Leveille SG, Buchner DM, Koepsell TD, McCloskey LW, Wolf ME, Wagner EH. Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology 1994; 5: 591598.
  • 10
    Ramaekers JG. Antidepressants and driver impairment: Empirical evidence from a standard on-the-road test. J. Clin. Psychiatry 2003; 64: 2029.
  • 11
    Robbe HW, O'Hanlon JF. Acute and subchronic effects of paroxetine 20 and 40 mg on actual driving, psychomotor performance and subjective assessments in healthy volunteers. Eur. Neuropsychopharmacol. 1995; 5: 3542.
  • 12
    Hindmarch I, Subhan Z, Stoker MJ. The effects of zimeldine and amitriptyline on car driving and psychomotor performance. Acta Psychiatr. Scand. Suppl.1983; 308: 141146.
  • 13
    Bye C, Clubley M, Peck AW. Drowsiness, impaired performance and tricyclic antidepressants drugs. Br. J. Clin. Pharmacol. 1978; 6: 155162.
  • 14
    Crome P, Newman B. A comparison of the effects of single doses of mianserin and amitriptyline on psychomotor tests in normal volunteers. J. Int. Med. Res. 1978; 6: 430434.
  • 15
    Peck AW, Bye CE, Clubley M, Henson T, Riddington C. A comparison of bupropion hydrochloride with dexamphetamine and amitriptyline in healthy subjects. Br. J. Clin. Pharmacol. 1979; 7: 469478.
  • 16
    Ogura C, Kishimoto A, Mizukawa R et al. Influence of single doses of dothiepin and amitriptyline on physiological measures and psychomotor performance in normal young and elderly volunteers. Neuropsychobiology 1983; 10: 103107.
  • 17
    Tiller JW. Antidepressants, alcohol and psychomotor performance. Acta Psychiatr. Scand. Suppl. 1990; 360: 1317.
  • 18
    Kinirons MT, Jackson SH, Kalra L, Trevit RT, Swift CG. Computerised psychomotor performance testing: A comparative study of the single dose pharmacodynamics of minaprine and amitriptyline in young and elderly subjects. Br. J. Clin. Pharmacol. 1993; 36: 376379.
  • 19
    Nathan PJ, Sitaram G, Stough C, Silberstein RB, Sali A. Serotonin, noradrenaline and cognitive function: A preliminary investigation of the acute pharmacodynamic effects of a serotonin versus a serotonin and noradrenaline reuptake inhibitor. Behav. Pharmacol. 2000; 11: 639642.
  • 20
    Iwamoto K, Takahashi M, Nakamura Y et al. The effects of acute treatment with paroxetine, amitriptyline, and placebo on driving performance and cognitive function in healthy Japanese subjects: A double-blind crossover trial. Hum. Psychopharmacol. 2008; 23: 399407.
  • 21
    Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC. Quantification of sleepiness: A new approach. Psychophysiology 1973; 10: 431436.
  • 22
    Jiang ZP, Shu Y, Chen XP et al. The role of CYP2C19 in amitriptyline N-demethylation in Chinese subjects. Eur. J. Clin. Pharmacol. 2002; 58: 109113.
  • 23
    Duverneuil C, de la Grandmaison GL, de Mazancourt P, Alvarez JC. A high-performance liquid chromatography method with photodiode-array UV detection for therapeutic drug monitoring of the nontricyclic antidepressant drugs. Ther. Drug Monit. 2003; 25: 565573.
  • 24
    Halling J, Weihe P, Brosen K. The CYP2D6 polymorphism in relation to the metabolism of amitriptyline and nortriptyline in the Faroese population. Br. J. Clin. Pharmacol. 2008; 65: 134138.
  • 25
    O'Hanlon JF, Haak TW, Blaauw GJ, Riemersma JB. Diazepam impairs lateral position control in highway driving. Science 1982; 217: 7981.
  • 26
    O'Hanlon JF. Driving performance under the influence of drugs: Rationale for, and application of, a new test. Br. J. Clin. Pharmacol. 1984; 18 (Suppl. 1): 121S129S.
  • 27
    Uchiyama Y, Ebe K, Kozato A, Okada T, Sadato N. The neural substrates of driving at a safe distance: A functional MRI study. Neurosci. Lett. 2003; 352: 199202.
  • 28
    Heaton RK. The Wisconsin Card Sorting Test (Manual). Psychological Assessment Resources, Odessa, FL, 1981.
  • 29
    Kashima H, Honda T, Kato M et al. Neuropsychological investigation on chronic schizophrenia-aspect of its frontal functions. In : Takahashi R, Flor-Henry P, Gruzelier J, Niwa S (eds). Cerebral Dynamics, Laterality and Psychopathology. Elsevier, Amsterdam, 1987; 337345.
  • 30
    Cornblatt BA, Risch NJ, Faris G, Friedman D, Erlenmeyer-Kimling L. The continuous performance test, identical pairs version (CPT-IP): I. New findings about sustained attention in normal families. Psychiatry Res. 1988; 26: 223238.
  • 31
    Callicott JH, Bertolino A, Mattay VS et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb. Cortex 2000; 10: 10781092.
  • 32
    Callicott JH, Egan MF, Mattay VS et al. Abnormal fMRI response of the dorsolateral prefrontal cortex in cognitively intact siblings of patients with schizophrenia. Am. J. Psychiatry 2003; 160: 709719.
  • 33
    van Laar MW, van Willigenburg AP, Volkerts ER. Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects. J. Clin. Psychopharmacol. 1995; 15: 3040.
  • 34
    Murphy FC, Michael A, Robbins TW, Sahakian BJ. Neuropsychological impairment in patients with major depressive disorder: The effects of feedback on task performance. Psychol. Med. 2003; 33: 455467.
  • 35
    Porter RJ, Gallagher P, Thompson JM, Young AH. Neurocognitive impairment in drug-free patients with major depressive disorder. Br. J. Psychiatry 2003; 182: 214220.
  • 36
    Airaksinen E, Larsson M, Lundberg I, Forsell Y. Cognitive functions in depressive disorders: Evidence from a population-based study. Psychol. Med. 2004; 34: 8391.
  • 37
    Richardson JS, Keegan DL, Bowen RC et al. Verbal learning by major depressive disorder patients during treatment with fluoxetine or amitriptyline. Int. Clin. Psychopharmacol. 1994; 9: 3540.